Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

sunnuntai 3. joulukuuta 2017 päivittänyt: Masonic Cancer Center, University of Minnesota

MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

PURPOSE: This phase I trial is studying the safety of donor umbilical cord blood transplant after fludarabine phosphate, cyclophosphamide, and total-body irradiation in treating patients with high-risk hematologic cancer (now closed).

The Phase II part of this trial is studying whether priming one of two UCB units with C3a facilitates engraftment of the treated unit.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

OUTLINE:

  • Nonmyeloablative preparative regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on day -6. Patients then undergo total-body irradiation on day -1. Some patients also receive anti-thymocyte globulin IV every 12 hours on days -6, -5, and -4.
  • Umbilical cord blood (UCB) transplantation: Patients undergo unmanipulated UCB transplantation followed by complement 3a fragment primed UCB transplantation on day 0.

Treatment for graft-vs-host disease prophylaxis is also given.

After completion of study therapy, patients are followed up periodically for up to 2 years.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

31

Vaihe

  • Vaihe 2
  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Minnesota
      • Minneapolis, Minnesota, Yhdysvallat, 55455
        • University of Minnesota Medical Center - Fairview

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 75 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Disease Criteria

    • Acute Leukemias: Must be in remission by morphology (<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse. (See exclusion criteria for more detailed definition)
    • Acute myeloid leukemia: high risk CR1 (as evidenced by preceding myelodysplastic syndrome (MDS), high risk cytogenetics such as those associated with MDS or complex karyotype, > 2 cycles to obtain complete remission (CR) or erythroblastic and megakaryocytic); second or greater CR.
    • Acute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk cytogenetics (e.g. t(9;22, t(1;19), t(4;11), other MLL rearrangements) or > 1 cycle to obtain CR; second or greater CR.
    • Burkitt's lymphoma in CR2 or subsequent CR
    • Natural Killer cell malignancies
    • Myeloproliferative syndromes/diseases: Chronic myelogenous leukemia (CML) in chronic or accelerated phase but patients must have failed or been intolerant to Imatinib mesylate. EXCLUDED: CML in refractory blast crisis, myelofibrosis, polycythemia vera, and essential thrombocytosis.
    • Myelodysplastic Syndrome: any subtype including refractory anemia (RA) if severe pancytopenia, high risk complex cytogenetics or International Prognostic Scoring System (IPSS) ≥ intermediate-2 (Int-2). Blasts must be less than 5%. If 5% or more requires therapy pre-transplant to reduce blast count to ≤5%. Patients who receive single agent 5-azacytidine, decitabine or immunomodulating drugs are eligible.
    • Large-cell lymphoma, Hodgkin's lymphoma and multiple myeloma: patients with chemotherapy sensitive disease that has failed or who are ineligible for an autologous transplant. Patients are eligible for umbilical cord blood (UCB) transplantation if there is no evidence of progressive disease by imaging modalities and/or biopsy. Persistent PET activity, though possibly related to lymphoma, IS NOT an exclusion criterion in the absence of computated tomography (CT) changes in size indicating progression. Large-cell and Hodgkin's lymphoma that is progressive on salvage therapy is NOT eligible. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
    • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma which have progressed after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
    • Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive. Mantle-cell lymphoma that is progressive on salvage therapy is NOT eligible. Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).
  • Umbilical Cord Blood Graft Selection - Two UCB units will be compose the graft, and each unit must be a 4-6 HLA-A, B, DRB1 antigen match to each other, as well as a 4-6 antigen match to the recipient. The combined cryopreserved nucleated cell dose of the 2 units must be ≥ 3 X 10^7/kg with each unit having a minimum cell dose of 1.5 X 10^7/kg. UCB units will be selected according to a common umbilical cord blood graft selection algorithm
  • Performance Status - adequate performance status defined as Karnofsky score ≥ 60
  • Age 18 to 70 years of age; patients ≥ 70 but ≤ 75 years are eligible if the co-morbidity score is ≤ 2
  • Organ Function

    • Cardiac: Left ventricular ejection fraction > 35%; absence of decompensated congestive heart failure; absence of uncontrolled arrhythmia
    • Pulmonary: DLCO > 30% of predicted; absence of O2 requirements
    • Hepatic: ALT, AST, alkaline phosphatase and bilirubin < 5 x upper limit of normal
    • Renal: Creatinine ≤ 2 mg/dl (patients with a creatinine > 1.2 or history of renal dysfunction must have calculated glomerular filtration rate (GFR) > 40 mL/min/1.73m2)
    • If recent mold infection e.g. Aspergillus - must have minimum of 30 days of appropriate treatment before transplant and infection controlled and be cleared by Infectious Disease.
    • The following conditions must be met:

      • If prior myeloablative autologous transplant, must be > 3 months but ≤ 12 months from transplant OR have received at least 2 cycles of multi-agent or highly immunosuppressive chemotherapy (i.e. induction for acute leukemia) within the 3 months preceding this study. OR
      • If neither prior myeloablative autologous transplant ≤ 12 months from transplant nor have received at least 2 cycles of multi-agent or highly immunosuppressive chemotherapy (i.e. induction for acute leukemia) within the 3 months preceding this study, patients are eligible as long as they receive equine anti-thymocyte globulin as part of the conditioning regimen.

Exclusion Criteria:

  • Patients who have an available, medically suitable, 5-6/6 HLA-A, B, DRB1 matched sibling donor
  • Patients who are eligible for autologous transplantation
  • Prior allogeneic transplant
  • Acquired or inherited bone marrow failure syndromes such as aplastic anemia and Fanconi anemia
  • Pregnant or breast feeding
  • Evidence of HIV infection or known HIV positive serology
  • Current uncontrolled serious infection
  • Active central nervous system malignancy

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Complement Fragment 3A - Small Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
200 cGy päivänä -1
50 mg/kg intravenously (IV) over 2 hours on Day -6.
Muut nimet:
  • Cytoxan
40 mg/m^2 over 1 hour on Days -6 through -2.
Muut nimet:
  • Fludara
On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
Kokeellinen: Complement Fragment A - Larger Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
200 cGy päivänä -1
50 mg/kg intravenously (IV) over 2 hours on Day -6.
Muut nimet:
  • Cytoxan
40 mg/m^2 over 1 hour on Days -6 through -2.
Muut nimet:
  • Fludara
On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Patients With the Complement 3a (C3a) Unit Predominating
Aikaikkuna: Day 180
Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.
Day 180

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Neutrophil Engraftment
Aikaikkuna: Day 42
Achieving 500 neutrophils/uL by day 42.
Day 42
Donor Chimerism in Blood
Aikaikkuna: Day 28
Percentage of donor DNA present in the peripheral blood
Day 28
Incidence of Grades II-IV Graft-vs-host Disease
Aikaikkuna: Day 0 through Day 100
Development of graft-versus-host disease through day 100.
Day 0 through Day 100
Non-Relapse Mortality
Aikaikkuna: Day 180
Deaths not due to relapse.
Day 180
Overall Survival
Aikaikkuna: Day 360
Survival (alive) from transplantation to last follow-up.
Day 360
Bone Marrow Chimerism
Aikaikkuna: Day 21
Percentage of donor DNA in the bone marrow.
Day 21
Chronic Graft-Versus-Host Disease
Aikaikkuna: Day 360
Patients who developed chronic graft-versus-host disease.
Day 360
Relapse of Disease
Aikaikkuna: Day 360
Patients who developed disease relapse after transplantation.
Day 360
Disease Progression
Aikaikkuna: Day 360
Patients who developed disease progression after transplantation.
Day 360
Platelet Recovery
Aikaikkuna: Day 180
Number of patients with >20,000 platelets/uL by day 180
Day 180
Donor Chimerism in Blood
Aikaikkuna: Day 60
Percentage of donor DNA present in the peripheral blood
Day 60
Incidence of Grades III-IV Graft-vs-host Disease
Aikaikkuna: 0 to 100 days
Development of graft-versus-host disease by day 100.
0 to 100 days
Non-relapse Mortality
Aikaikkuna: Day 360
Deaths not due to relapse.
Day 360
Overall Survival at Day 720
Aikaikkuna: 720 days
Survival (alive) from transplantation to last follow-up at day 720.
720 days
Relapse of Disease
Aikaikkuna: Day 720
Patients who developed disease relapse after transplantation.
Day 720
Disease Progression
Aikaikkuna: Day 720
Patients who developed disease progression after transplantation.
Day 720
Donor Chimerism
Aikaikkuna: Day 100
Percentage of donor DNA in the bone marrow.
Day 100
Donor Chimerism
Aikaikkuna: Day 180
Percentage of donor DNA in the bone marrow.
Day 180
Donor Chimerism
Aikaikkuna: Day 360
Percentage of donor DNA in the bone marrow.
Day 360

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Claudio G. Brunstein, MD, PhD, Masonic Cancer Center, University of Minnesota

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus

Maanantai 1. maaliskuuta 2010

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 1. elokuuta 2012

Opintojen valmistuminen (Todellinen)

Torstai 1. elokuuta 2013

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 21. elokuuta 2009

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 21. elokuuta 2009

Ensimmäinen Lähetetty (Arvio)

Maanantai 24. elokuuta 2009

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 28. joulukuuta 2017

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 3. joulukuuta 2017

Viimeksi vahvistettu

Perjantai 1. joulukuuta 2017

Lisää tietoa

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa